The 31st Annual National Jewish Health Pulmonary and Allergy Update was held February 4-7, 2009 at the Keystone Conference Center in Keystone, Colorado. National Jewish Health, the #1 respiratory hospital in the nation as ranked by U.S. News & World Report for the past 11 consecutive years, brought together its world class faculty with physicians and allied health professionals from around the country. The Highlights Newsletter provides summary highlights of several of the presented lectures to share current information with those who were unable to attend the meeting.

Target Audience

Allergists, Pulmonologists, Family Practice Physicians, Physician Assistants, Nurse Practitioners and other interested allied health professionals.

Accreditation and Designation Statement

National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

National Jewish Health designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

National Jewish Participating Faculty

Dan Atkins, MD
Head, Associate Professor, Division of Ambulatory Pediatrics, Dept. of Pediatrics
Medical Director of the Pediatric Day Program

Ronald Balkissoon, MD
Associate Professor, Pulmonary Division
Department of Medicine

Rohit Katial, MD
Professor, Department of Medicine
Program Director, Allergy & Immunology
Director, Weinberg Clinical Research Unit

Esther L. Langmack, MD
Director of Faculty and Community Education
Associate Professor, Department of Medicine

Richard Martin, MD
Chairman, Department of Medicine
Edelstein Family Chair in Pulmonary Medicine
Professor, Department of Medicine

Harold Nelson, MD
Professor, Division of Allergy and Clinical Immunology
Department of Medicine

E. Rand Sutherland, MD, MPH
Medical Director, Pulmonary Physiology Unit
Associate Professor, Department of Medicine

Disclosure Information Listed for CME Content Development and Approval Committee and Participating Program Faculty

In accordance with the Accreditation Council for Continuing Medical Education, National Jewish Health requires that all program faculty, content developers, CME approval committee, and medical writers in a position to control the content of this activity are expected to disclose any or not significant financial interest or other relationship with any proprietary entity producing health care goods or services, with the exemption of non-profit or governmental organizations and non-health care related companies. Our goal is to ensure that there is no compromise of the ethical relationship that exists between those in a position to control the content of the activity and those attending the activity and their respective professional duties.

Significant financial interest is defined as receiving, or in the past twelve months having received, a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., Stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected.

All CME Educational Activities sponsored by National Jewish Health are reviewed by our faculty CME committee to ensure a balanced and evidence-based presentation. Any potential conflict of interest among program faculty has been identified and resolved according to ACCME guidelines.

Key

A - Advisory Board      B - Board of Directors       C- Consultant       E- Employee
F - Founder       I - Investigator      O - Other      SP- Speaker       SH - Stockholder

Dan Atkins, MD
Has no significant financial interest to report

Ronald Balkissoon, MD
A - AstraZeneca
SP - AstraZeneca, Boehringer Ingleheim, Dey, Genentech, GlaxoSmithKline, Novartis

David Beuther, MD
SP - AstraZeneca

Ronina Covar, MD
A - Merck
I - Ross Abbott

Stephen K. Frankel, MD
Has no significant financial interest to report

Rohit Katial, MD
A - Alcon
SP - GlaxoSmithKline, Teva

Esther L. Langmack, MD
Has no significant financial interest to report

Richard Martin, MD
A - Genentech, Novartis, Schering-Plough, Teva
C - Genentech, GlaxoSmithKline, Kalobios , Novartis, Teva
I - GlaxoSmithKline

Harold S. Nelson, MD
C - Abbott, AstraZeneca, Boehringer-Ingelheim, Dey, L.P., Dynavax Technologies, Dyson, Genentech, GlaxoSmithKline, Johnson & Johnson, MediciNova, Novartis, Schering- Plough, Sepracor, Teva
I - Altana, AstraZeneca, Boehringer-Ingelheim, Ception, Genentech, Novartis, Schering-Plough, Sepracor, Wyeth
SP - AstraZeneca , GlaxoSmithKline

E. Rand Sutherland, MD, MPH
A - Dey, L.P., GlaxoSmithKline
C - GlaxoSmithKline, Schering-Plough
I - Boehringer-Ingelheim, Novartis

Commercial Support

This activity is sponsored by National Jewish Health and supported by educational grants from: GlaxoSmithKline, sanofi-aventis, and UCB.